Skip to main content

Fludarabine Injection Shortage

Last Updated: April 7, 2024
Status: Current

Reason for the Shortage
    • Areva has fludarabine 25 mg/mL 2 mL vials available for direct orders only.
    • Fresenius Kabi has fludarabine injection available.
    • Pfizer discontinued fludarabine in August 2020. Their estimated market share was less than 1%.
    • Sagent has fludarabine injection available.
    • Teva is not currently marketing 25 mg/mL 2 mL vials. The 50 mg lyophilized powder for injection vials are available.
Available Products
    • Fludarabine intravenous solution for injection, Areva, 25 mg/mL, 2 mL vial, 1 count, NDC 59923-0604-02
    • Fludarabine intravenous solution for injection, Fresenius Kabi, 25 mg/mL, 2 mL vial, 1 count, NDC 63323-0192-02
    • Fludarabine intravenous solution for injection, Sagent, 25 mg/mL, 2 mL vial, 1 count, NDC 25021-0242-02
    • Fludarabine intravenous lyophilized powder for injection, Teva, 50 mg, vial, 1 count, NDC 45963-0609-55

Estimated Resupply Dates

    • All currently marketed presentations are available.

Alternative Agents & Management

    • Consider evaluating the health-care system's total supply of fludarabine before beginning patients on combination chemotherapy regimens containing fludarabine. If adequate supplies are not available, select an alternative regimen.
    • The choice of an alternative agent must be patient-specific and based on renal function, liver function, and the neoplasm type and location. No single agent can be substituted for fludarabine.
    • Consult a Hematology/Oncology specialist for patient- and neoplasm-specific recommendations.
    • Refer to the ASHP Guidelines on Managing Drug Product Shortages for more guidance on developing a multidisciplinary plan when the supply must be allocated.
    • Refer to national guidelines such as those from the National Comprehensive Cancer Network ( or American Society of Clinical Oncology ( for additional information regarding therapeutic use.


Updated April 7, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created December 17, 2019 by Stephen Andrews, PharmD, BCPS, CPPS, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.